A Case of Complete Regression of Hepatocellular Carcinoma during Administration of COX-2 Inhibitor |
Hae Jung Song, M.D., Yun Soo Kim, M.D.2, Chang Hee Han, M.D., Jae Young Jang, M.D.,
Jung Hoon Kim, M.D.1, Young Koog Cheon, M.D., Young Seok Kim, M.D., Jong Ho Moon, M.D.,
Young Deok Cho, M.D., Chan Sup Shim, M.D., Kui Hyang Kwon, M.D.1, and Boo Sung Kim, M.D. |
Institute for Digestive Research, Department of Internal Medicine, Department of Radiology1, Soon Chun Hyang University, College of Medicine, Seoul, Department of Gastroenterology and Hepatology, Gil Medical Center, Gachon University2, Incheon, Korea |
|
|
ABSTRACT |
|
Overexpression of cyclooxygenase-2 (COX-2) has been associated with hepatocarcinogenesis. Inhibitors of COX-2 have proapoptotic and antiproliferative effects on malignant tumors and inhibit tumor invasion to the surrounding tissues. We report here a case of complete regression of advanced hepatocellular carcinoma (HCC) during COX-2 inhibitor administration. An eighty-year-old female was diagnosed as an advanced HCC, which was associated with HCV infection. She received COX-2 inhibitor for 3 months due to degenerative arthritis of both knees. Tumor enhancement on arterial phase CT completely disappeared without specific treatment for the HCC, and the tumor size decreased on the follow-up CT scan. (Korean J Hepatol 2006; 12:449-454) |
KeyWords:
Hepatocellular carcinoma; Complete regression; COX-2 inhibitor; Celecoxib |
|
|